Bayer CropScience



January 30, 2014

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001

COMPANY CODE: 506285 SCRIP ID: BAYER

Dear Sir / Madam

Sub.: Unaudited Financial Results for the Quarter ended December 31, 2013 and Limited Review Report

In terms of clause 41 of the Listing Agreement, we are pleased to furnish the unaudited financial results of the Company for the quarter ended December 31, 2013 and the Limited Review Report thereon from the statutory auditors M/s. Price Waterhouse (Firm Registration no. 301112E).

Kindly acknowledge receipt.

Thanking you,

Yours faithfully for Bayer CropScience Limited

Rajiv Wani Vice President – Law, Patents & Compliance & Company Secretary

Encl: As above

Bayer CropScience Limited Kolshet Road Thane - 400 607 Maharashtra, India

Tel. + 91 22 2531 1234 Fax + 91 22 2545 5063 www.bayercropscience.com www.bayer.co.in

Registered Office : Olympia, First Floor Central Avenue, Hiranandani Gardens, Powai, Mumbai - 400 076

Bayer CropScience

1

÷.



BAYER CROPSCIENCE LIMITED (Regd. Office: Olympia, First Floor, Central Avenue, Hiranandani Gardens, Powai, Mumbai - 400 076)

PARTICULARS	Quarter Ended			Year to Date		Previous Year Ended	
	31.12.2013 UNAUDITED	30.09.2013 UNAUDITED	31.12.2012 UNAUDITED	31.12.2013 UNAUDITED	31.12.2012 UNAUDITED	31.03.2013 AUDITED	
Income from operations	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
Net Sales/ Income from Operations (Net of excise duty)	6,266	10,274	5,591	26,203	22,586	26,	
Other Operating Income	278	230	284	722	762		
Total income from operations (net)	6,544	10,504	5,875	26,925	23,348	27,	
Expenses							
Cost of Materials Consumed	1,907	2.011	1,240	5,114	4,006	5	
Purchases of stock-in-trade	1,233	4,072	908	12,077	10,489	11	
Changes in inventories of finished goods, work-in-progress and stock-in-trade	832	618	1,487	309	455		
Employee Benefits Expense	549	480	450	1,581	1,378	1	
Depreciation and Amortisation Expense (including Impairment) (Notes 3 and 4)	113	343	95	539	270		
Other Expenses	1,540	1,474	1,157	4,334	3,532		
Total Expenses	6,174	8,998	5,337	23,954	20,130	24,	
Profit from Operations before other income, finance costs and exceptional items	370	1,506	538	2,971	3,218	3,	
Other Income	234	279	115	744	477		
Profit from ordinary activities before finance costs and exceptional items	604	1,785	653	3,715	3,695	3.	
inance costs	7	7	12	20	25		
Profit from ordinary activities after finance costs but before exceptional items	597	1,778	641	3,695	3,670	3	
Add/ (Less) Exceptional items :							
Profit on Sale of Land and Buildings (Note 5)		-	11,083		11,083	11	
Demolition and Remediation (Expenditure) (net) (Note 6)	-	-	96		(183)		
Exceptional Items			11,179		10,900	11,	
Profit from ordinary activities before tax	597	1,778	11,820	3,695	14,570	15	
Current and Deferred Tax expense (net of credits)	207	613	2,786	1,262	3,671	4	
Net Profit from ordinary activities after tax	390	1,165	9,034	2,433	10,899	11,	
Paid-up equity share capital (Face Value ₹ 10/-)	366	395	395	366	395		
Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						1	
Earnings per share (basic and diluted) (not annualised) (in ₹) (Note 7)	10.14	29.49	228.72	62.14	275.94	29	

PART II SELECT INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2013

PARTICULARS	Quarter Ended			Year to Date		Previous Year Ended	
	31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	31.03.2013	
A PARTICULARS OF SHAREHOLDING (Note 8)							
Public Shareholding							
Number of shares	11,368,094	11,412,085	11,412,085	11,368,094	11,412,085	11,412,085	
Percentage of shareholding (%)	31.04%	28.89%	28.89%	31.04%	28.89%	28.89%	
Promoters and Promoter Group Shareholding							
Pledged/ Encumbered							
- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil	
 Percentage of shares (as a % of total shareholding of promoter and promoter group) 	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
- Percentage of shares (as a % of total share capital of the Company)	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
Non-Encumbered							
- Number of shares	25,250,907	28,086,662	28,086,662	25,250,907	28,086,662	28,086,662	
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	
- Percentage of shares (as a % of total share capital of the Company)	68.96%	71.11%	71.11%	68.96%	71.11%	71.119	

	PARTICULARS	3 months ended 31.12.2013
в	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil

9 K



Bayer CropScience



BAYER CROPSCIENCE LIMITED (Regd. Office: Olympia, First Floor, Central Avenue, Hiranandani Gardens, Powal, Mumbai - 400 076)

NOTES:

- 1 The Company has only one reportable business segment, i.e. *Agri Care*. The Company's business is seasonal in natu:e and hence quarterly figures are not representative of the full year's performance.
- 2 Consistent with past practice, Sales for the nine months ended December 31, 2013 are net of estimated returns of ₹ 842 Millions (April December 2012 ₹ 667 Millions), in respect of seasonal sales, which, in Management's opinion, may need to be reviewed dependent on future circumstances. Sales returns are accounted at actuals at the financial year-end.
- 3 Pursuant to the Board of Director's approval for proposal to sell either the whole or in part the manufacturing unit(s) and facilities of the Company located at Ankleshwar and subsequent execution of 'Business Transfer Agreement' to sell, convey, assign and transfer chemical manufacturing facility at Ankleshwar, as a going concern on slump sale basis, to Deccan Fine Chemicals (India) Private Limited and 'Assets Transfer Agreement' to sell and transfer all assets related to Poly-isocyanate unit located within the Ankleshwar and subsequent execution of 'Business Transfer Agreement' to sell and transfer all assets related to Poly-isocyanate unit located within the Ankleshwar facility to Bayer MaterialScience Private Limited, the Company has recognized net impairment loss of ₹ 154 Million during nine months ended December 31, 2013 (loss of ₹ 177 Million for the quarter ended September 30, 2013 and reversal of loss of ₹ 23 Million for the quarter ended December 31, 2013). The sale pursuant to both the agreements will be recognised subject to satisfactory fulfillment of certain conditions and receipt of such government approval or permission, as may be required.
- 4 The Depreciation and Amortization Expense for the quarter ended December 31, 2013, quarter ended September 30, 2013 and nine months ended December 31, 2013 includes additional depreciation charge of ₹ 40 Million, ₹ 82 Million, rt 82 Million and rt 122 Million, rt 82 Million and revision in economic useful life of the fixed assets of the Company effective from April 1, 2013.
- 5 This represents profit from sale of Thane Land and Buildings ₹ 11,083 Millions and ₹ 823 Millions from sale of Powai Building during the previous year ended March 31, 2013.
- 6 The Bayer Companies worldwide place great importance on protecting the environment and conserving natural resources. Pursuant to the cessation of manufacturing activities at Thane, the Company had incurred expenditure towards Demolition and Remediation activities.

7	7 PARTICULARS	Quarter Ended			Year to Date		Previous Year Ended	
		31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	31.03.2013	
	Earnings per share Before Exceptional Items (net of Tax) (basic & diluted) (not annualised) (in र)	10.14	29.49	11.13	62.14	63.11	66.79	

- 8 Pursuant to the approval of the Board of Directors on July 22, 2013 and Shareholders of the Company through postal ballot, results of which were declared on September 16, 2013, the Company bought back 2,879,746 equity shares (representing 7.29% of the equity capital) at a price of ₹1,580/- per equity share aggregating to ₹ 4,549,998,680/-, through the tender offer route, in terms of Public Announcement dated September 18, 2013. After extinguishment of 2,879,746 Equity Shares on November 29, 2014, the Issued, Subscribed and Paid-up Equity Capital of the Company reduced from 39,498,747 equity shares to 36,619,001 equity shares.
- 9 The Board of Directors at its meeting held on January 30, 2014 accepted resignation of Mr. Stephan Gerlich as Vice Chairman and Managing Director of the Company to be effective from closing hours of January 31, 2014. At the same meeting the Board appointed Mr. Richard van der Merwe as Executive Director of the Company, with the designation as Vice Chairman & Managing Director, to be effective from February 1, 2014.
- 10 The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on January 30, 2014 and the statutory auditors have carried out a limited review of the results for the quarter ended December 31, 2013.
- 11 Previous period's figures have been regrouped wherever necessary.

of the Board Klln

Dr. Thomas Hoffmann

Whole-time Director

Place : Mumbai Date : January 30, 2014

as



The Board of Directors Bayer CropScience Limited Olympia, First Floor, Central Avenue Hiranandani Gardens, Powai Mumbai – 400 076

- 1. We have reviewed the results of Bayer CropScience Limited (the "Company") for the quarter ended December 31, 2013 which are included in the accompanying 'Statement of un-audited financial results for the quarter and nine months ended December 31, 2013' (the "Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the Management but have neither been reviewed nor been audited by us. The Statement has been prepared by the Company pursuant to Clause 41 of the Listing Agreement with the Stock Exchanges in India, which has been initialled by us for identification purposes. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
- 2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
- 3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- 4. We have only traced the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' in the Statement from the disclosures made by the Management and are, therefore, not expressing a review opinion thereon.
- 5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Firm Registration Number: 301112E Chartered Accountants

U. A. Hah

U**day Shah** Partner Membership Number: 046061

Place: Mumbai Date: January 30, 2014